8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):  March 6, 2014 (March 6, 2014)

CHEMBIO DIAGNOSTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada	0-30379	88-0425691
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification Number)
	3661 Horseblock Road
	Medford, NY 11763
	(Address of principal executive offices)
	631-924-1135
	(Registrant's Telephone Number)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01.  REGULATION FD DISCLOSURE.

On March 6, 2014, the Company issued a press release entitled "Chembio Diagnostics Reports 2013 Financial Results".   A copy of the press release is furnished herewith as Exhibit 99.1.

On March 6, 2014, the Company posted a PowerPoint Presentation to their website entitled "Investor Presentation March 2014."  A copy of the presentation is furnished herewith as Exhibit 99.2.

In addition, also on March 6, 2014, the Company posted an Investor Fact Sheet to their website.  A copy of the fact sheet is furnished herewith as Exhibit 99.3

The information in this Item 7.01 of this Form 8-K is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Form 8-K also shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference.

ITEM 9.01.FINANCIAL STATEMENTS AND EXHIBITS

Exhibits.

99.1	Press Release entitled "Chembio Diagnostics Reports 2013 Financial Results" dated March 6, 2014.
99.2	Presentation entitled "Investor Presentation March 2014" dated March 6, 2014.
99.3	Investor Fact Sheet posted to the company website dated March 6, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

March 6, 2014                                                   Chembio Diagnostics, Inc.

By:    /s/ Lawrence A. Siebert                                      

Lawrence A. Siebert

Chief Executive Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release entitled "Chembio Diagnostics Reports 2013 Financial Results" dated March 6, 2014.
99.2	Presentation entitled "Investor Presentation March 2014" dated March 6, 2014.
99.3	Investor Fact Sheet posted to the company website dated March 6, 2014.

EX-99.1

Chembio Diagnostics Reports 2013 Financial Results

Conference Call and Webcast Today at 10:00 a.m. Eastern

MEDFORD, NY, March 6, 2014 -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today reported financial results for the quarter and year ended December 31, 2013, which include record revenues, and a tenth consecutive year of double-digit organic revenue growth.

Financial highlights for fiscal year 2013 include the following (all comparisons are with fiscal year 2012):

• Total revenues of $29.55 million, up 15% compared with $25.61 million

• Product sales of $27.52 million, up 13% compared with $24.33 million

• Operating income of $1.00 million, compared with $1.45 million

• Net income of $531,000, or $0.06 per diluted share, compared with $941,000, or $0.11 per diluted share

Financial highlights for the 2013 fourth quarter include the following (all comparisons are with the 2012 fourth quarter):

• Total revenues of $7.86 million, down .1% compared with $7.87 million

• Product sales of $7.10 million, down 4% compared with $7.41 million

• Operating loss of $176,000, compared with operating income of $705,000

• Net loss of $262,000, or $0.03 per diluted share, compared with net income of $492,000, or $0.06 per diluted share

Lawrence Siebert, Chembio's Chief Executive Officer, stated, "During 2013, Chembio made great strides in expanding the international reach for its products.  We are experiencing particularly strong demand for our unique DPP® HIV-Syphilis product that we launched in Mexico in the fourth quarter and, with the addition of new sales and distribution assets in Asia, Africa, and Europe, and ongoing growth opportunities in North America and South America, we have a great platform for continued growth of this and other products in our portfolio."

"A key strategic investment for Chembio is establishing a commercial sales organization in the U.S. to market Chembio-branded products.  We have begun to do this as we have a robust pipeline of products that will be marketed under the Chembio-brand in the medium and long term, including our DPP® HIV 1/2 Assay for use with oral fluid or blood samples."

"We believe 2014 will be a transformational year for Chembio.  Following our fifth consecutive year of profitability, we began 2014 with the strongest balance sheet in our history.  We will continue to invest in providing our customers worldwide with innovative products that help people to live longer and healthier lives."

Full Year 2013 Results

Total revenues for fiscal year 2013 of $29.55 million were up 15% compared with total revenues of $25.61 million in the prior-year period. Product sales in the 2013 year of $27.52 million were up 13% compared with product sales of $24.33 in the prior-year period, primarily due to stronger sales of lateral flow technology products, particularly, in South America and partially offset by declines in DPP® product sales in Brazil to FIOCRUZ.  The research and development ("R&D"), milestone, grant and royalty revenues for 2013 increased to $2.03 million from $1.28 million in the prior-year period.

Gross margin for the 2013-year increased 14% to $12.30 million compared with $10.79 million for the prior-year period, due primarily to the increase of products sold. Product gross margin 2013 increased 8%, to $10.27 million, from $9.51 million in the prior-year period.

R&D expenses in the year of 2013 were $5.83 million, compared with $4.49 million in the prior-year period. The 2013 year included $1.52 million of clinical trial expenses related to our DPP® HIV 1/2 Assay CLIA waiver study, compared with $820,000 of total clinical trial expenses in the prior-year period.

Selling, general and administrative expenses in 2013 increased 13% to $5.46 million from $4.85 million in the prior-year period, largely due to wages and related expenses, and other expenses, partially offset by lower commissions paid on DPP® product sales to Brazil.

Operating income for 2013 was $1.00 million, compared with operating income of $1.45 million for the prior-year period.

Net income for 2013 was $531,000, or $0.06 per diluted share, compared with net income of $941,000, or $0.11 per diluted share, for the prior-year period.

Fourth Quarter Results

Total revenues for the fourth quarter of 2013 of $7.86 million were down 0.1% compared with total revenues of $7.87 million in the prior-year period. Product sales in the 2013 fourth quarter of $7.10 million were down 4% compared with product sales of $7.41 million in the prior-year period.  Research and development ("R&D"), milestone, and grant and royalty revenues for the three months ended December 31, 2013 increased to $764,000 from $458,000 in the prior-year period.

Gross margin for the 2013 fourth quarter increased 3.5% to $3.27 million compared with $3.16 million for the prior-year period, due primarily to the higher amount of R&D, milestone, and grant and royalty revenues. The amount of product gross margin for the fourth quarter of 2013 decreased 7% to $2.50 million, from $2.70 million in the prior-year period.

R&D expenses in the fourth quarter of 2013 were $1.69 million, compared with $1.12 million in the prior-year period. The 2013 fourth quarter included $490,000 of clinical trial expenses related to our DPP® HIV 1/2 Assay CLIA waiver study, compared with $157,000 in the prior-year period.

Selling, general and administrative expenses in the fourth quarter of 2013 increased to $1.76 million from $1.33 million in the prior-year period, largely due to increased wages and related costs.

Operating loss for the fourth quarter of 2013 was $176,000, compared with an operating income of $705,000 for the prior-year period.

Net loss for the fourth quarter of 2013 was $262,000, or $0.03 per diluted share, compared with net income of $492,000, or $0.06 per diluted share, for the prior-year period.

Balance Sheet Highlights

The Company had cash and cash equivalents of $9.65 million as of December 31, 2013, compared with $2.95 million as of December 31, 2012. The primary reason for this increase was net cash received from the April 2013 common stock funding of $5.40 million. Additional cash for the year was provided from net income plus non-cash expenses of $1.90 million and from a decrease in accounts receivables of $263,000, together with increased accounts payable and other accrued liabilities of $982,000. Partially offsetting these provisions was a use of cash for increased inventories of $701,000 and for other items of $162,000. Overall, working capital increased by $6.59 million during the year from $7.63 million to $14.22 million.

Conference Call

To participate on the conference call, please dial (877) 407-0778 from the U.S. or (201) 689-8565 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until March 13, 2014 at 11:59 p.m. Eastern Time by dialing (877) 660-6853 from the U.S. or (201) 612-7415 from outside the U.S. and entering conference ID #:13576790. The conference call may also be accessed via the Internet at http://www.investorcalendar.com/IC/CEPage.asp?ID=172309.  An archive of the webcast will be available for 90 days on the Company's website at www.chembio.com.

Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of Chembio's website at www.chembio.com.  To listen to the live call, please go to the website 15 minutes prior to its start to register, download, and install the necessary audio software.  A replay will be available on the website for a limited time.

About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $10 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by Alere, Inc. (formerly, Inverness Medical Innovations, Inc.). Chembio markets its HIV STAT-PAK® line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP®) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP®. Headquartered in Medford, NY, with approximately 200 employees, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U.S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13.485. For more information, please visit: www.chembio.com.

Forward-Looking Statements

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements, which are estimates only, reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing and to obtain regulatory approvals in a timely manner, as well as the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

(Tables to follow)

Contacts:

Chembio Diagnostics

Susan Norcott

(631) 924-1135, ext. 125

snorcott@chembio.com

Vida Strategic Partners (investor relations)

Stephanie C. Diaz

(415) 675-7401

sdiaz@vidasp.com

Chembio Diagnostics, Inc. & Subsidiary
Summary of Consolidated Results of Operations
	For the three months ended					For the years ended
	December 31, 2013			December 31, 2012			December 31, 2013		December 31, 2012
Net product sales	$	7,096,191		$	7,407,919		$	27,515,786	$	24,327,355
License and royalty revenue		4,008			-			4,906		-
R&D, milestone and grant revenue		760,096			458,147			2,028,917		1,283,240
TOTAL REVENUES	$	7,860,295		$	7,866,066		$	29,549,609	$	25,610,595
GROSS MARGIN	$	3,268,908		$	3,157,589		$	12,300,159	$	10,789,991
Research and development expenses	$	1,686,048		$	1,122,483		$	5,834,249	$	4,486,302
Selling, general and administrative expenses	$	1,758,902		$	1,330,035		$	5,461,083	$	4,851,587
(LOSS) INCOME FROM OPERATIONS	$	(176,042	)	$	705,071		$	1,004,827	$	1,452,102
OTHER INCOME (EXPENSE):	$	2,067		$	603		$	12,943	$	(1,584	)
Income tax provision	$	88,012		$	214,017		$	486,952	$	509,237
NET (LOSS) INCOME	$	(261,987	)	$	491,657		$	530,818	$	941,281
Basic (loss) earnings per share	$	(0.03	)	$	0.06		$	0.06	$	0.12
Diluted earnings (loss) per share	$	(0.03	)	$	0.06		$	0.06	$	0.11
Weighted average number of shares outstanding, basic		9,324,783			8,020,525			8,994,080		7,986,030
Weighted average number of shares outstanding, diluted		9,324,783			8,638,205			9,519,968		8,614,944

Chembio Diagnostics, Inc. & Subsidiary
Summary of Consolidated Balance Sheets
	December 31, 2013			December 31, 2012
CURRENT ASSETS:
Cash and cash equivalents	$	9,650,275		$	2,951,859
Accounts receivable, net of allowance for doubtful accounts of $24,000 and $58,000 at December 31, 2013 and 2012, respectively		4,592,121			4,821,357
Inventories		3,188,726			2,488,071
Prepaid expenses and other current assets		1,099,379			747,463
TOTAL CURRENT ASSETS		18,530,501			11,008,750
FIXED ASSETS, net of accumulated depreciation		1,978,232			1,427,646
OTHER ASSETS:		3,977,859			4,898,754
TOTAL ASSETS	$	24,486,592		$	17,335,150
CURRENT LIABILITIES:
Accounts payable and accrued liabilities		4,309,490			3,303,923
Current portion of loans payable		-			51,236
Customer deposits		-			23,224
TOTAL CURRENT LIABILITIES		4,309,490			3,378,383
Loans payable - net of current portion		-			82,247
TOTAL LIABILITIES		4,309,490			3,460,630
STOCKHOLDERS' EQUITY:
Common stock - $.01 par value; 100,000,000 shares authorized, 9,324,783 and 8,036,232 shares issued and outstanding for 2013 and 2012, respectively		93,248			80,362
Additional paid-in capital		46,875,027			41,116,149
Accumulated deficit		(26,791,173	)		(27,321,991	)
TOTAL STOCKHOLDERS' EQUITY		20,177,102			13,874,520
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	24,486,592		$	17,335,150

Chembio Diagnostics, Inc. & Subsidiary
Summary of Consolidated Cash Flow
For the years ended
	December 31, 2013			December 31, 2012
Net cash provided by operating activities	$	2,277,614		$	761,084
Net cash used in investing activities		(885,609	)		(872,442	)
Net cash provided by (used in) financing activities		5,306,411			52,263
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	$	6,698,416		$	(59,095	)

EX-99.2

RAPID Tests for EARLIER Treatment

Investor Presentation March 2014

Slide 2

Forward Looking Statements

Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.  Those statements include statements regarding the intent, belief or current expectations of Chembio and its management. Such statements reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, Chembio's ability to develop, manufacture, market and finance new products and the demand for Chembio's products.  Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Other factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

Slide 3

Investment Summary

• Develops, Manufactures & Markets Point-of-Care Diagnostic Tests (POCTs)

‐ Global Sales – Direct and Through Partnerships

‐ $8B Global Market with Current Pipeline Addressing $650MM Segment

• Five Consecutive Years of Profitability & Revenue Growth

‐ 2013 Revenues and Product Gross Margin Increased by 15% and 8% respectively vs. 2012

• Patented DPP® - A Platform POCT Technology

‐ Uniquely Enables Multiplexing for Higher Value Tests & Increased Sensitivity

‐ DPP® Oral Fluid HIV Test – FDA-Approved - CLIA waiver pending

‐ DPP® HIV-Syphilis  Test- Strong outlook for international sales in 2014

• Growing Pipeline of DPP® POCT Products

‐ DPP® HCV Ab & HIV Ag-Ab Test

Slide 4

Our Vision & Mission

We are a provider of Point-of-Care diagnostic tests and solutions, helping people live longer and healthier lives.

Our Mission is to become a key provider in the market for rapid diagnostic Point of Care (POC) testing, through the development, manufacture, and commercialization of proprietary technology with superior performance and technical service.

Slide 5

Chembio Products are well Positioned Globally for Growth…

USA

• Lateral Flow Productes Distributed through Alere (30% FY13 revenue)

• DPP® HIV PMA approval (Dec'12) / CLIA pending

• Funded Research Collaborations with CDC, DOD, NIH (6% FY13)

EU

• CE mark approval for SURECHECK® (July'13)

• CE mark for STATPAK®, DPP® HIV HIV/Syphilis pending

ASIA

· Feb. 2014 License, Distribution, Tech. Transfer and Contract Manufacturing Agreements

AFRICA

• Procurements primarily funded by PEPFAR, Global Fund, and WHO

• Sales channel; NGO-direct  & through distributors (14% FY13 revenue)

• Commercial resource deployment

SOUTH/CENTRAL AMERICA

• Strong OEM Partnerships (FIOCRUZ, Labtest); Branded products sold to NGOs, private  distributors (45% FY13)

Slide 6

POCTs - A Growing $8B Global Market

Long-term Trend Toward  Molecular Levels of Detection

CURRENT CAPABILITIES

· Lateral Flow Technology

· Single Parameter Tests

· DPP® Technology Enabling Improved Sensitivity, Multiplexing

R&D

· Signal Enhancement  Features

POTENTIAL NEW CAPABILITIES BEING ASSESSED

· Molecular

· Amplification Technologies

Slide 7

Chembio's Lateral Flow Rapid HIV Tests Marketed World-Wide

• Total $20.2MM  FY 2013

• 50%  Increase vs. FY2012

• 5-8.5% Royalties ending Feb. 2015

• In U.S. Market Sold Exclusively through Alere

‐ $8.9MM in FY 2013

‐ 14% Increase vs. FY2012

‐ Exclusivity May Be Terminated in 2014

• International Market Sold Through Multiple Channels

‐ $11.8MM in FY2013

‐ 84.5% Increase vs. FY2012

See graphics

Slide 8

Chembio's Dual Path Platform (DPP®) Patented Point-of-Care Test Technology

· Proprietary Platform Technology that Uniquely Enables Multiplexing for Higher Value Tests

· Increases Sensitivity as Compared with Lateral Flow Technology

· Validated with Numerous Partners, Regulatory Agencies

· New DPP® Patents Issued in 2013

See graphics

Slide 9

Chembio's  Pipeline: $650MM Total Addressable Market

Chembio Pipeline POCT	Total Estimated Market Opportunity	Targeted Launch
HIV POCT – U.S.	$75 MM	$8.9MM Product Sales 2013 ; New Oral Fluid Product Launch 2014
HIV-Syphilis - U.S	$75 MM	2015
Hepatitis C POCT – U.S.	$100 MM	2016
Combined Estimated Market for Above Products – ex-U.S.	$400 MM	$27.5MM  Product Sales in FY2013 Significant Growth Opportunities with Current and New Products
TOTAL:	$650MM

Slide 10

Chembio POCT Market  Opportunities: HIV Rapid POCTS

Established, Growing Markets

U.S.

• ~50,000 New Infections in 2012

• USPSTF Recommends Routine Testing

‐ ACA Expanding Coverage by 25MM+

International

• 2.5 MM New Infections Worldwide in 2012

• Designation in PEPFAR & Other Donor-Funded Countries' Testing Protocols

See graphic

Slide 11

Chembio DPP® HIV 1/2 Assay FDA-Approved Dec. '12 CLIA Waiver Application Filed with FDA November 2013,  Anticipated Launch in 2nd half of 2014

· Build on Established  Position/Performance  of Our FDA Lateral  Flow Products with Only Alternative to Current  ~$35MM Oral Fluid Product

· Superior Blood Matrix Performance over Top 4 Market Share Products in Early Detection Study

· Superior Oral Fluid Sensitivity v. Market Leader in Only Head-to-Head Study

· User Friendly, Safe and Efficient SampleTainer™ Sample Collection System

· Separate and Reagent-Free Oral Fluid Collection Device

See graphics

Slide 12

DPP® HIV-Syphilis Multiplex Assay

‐ Large Global Market Opportunities for Pre-Natal and MSM Screening

‐ Higher Prevalence of  Syphilis (1.9MM) than HIV (1.5MM) in Pregnant Women

‐ International & US Regulatory Approval and Commercialization Efforts Underway

‐ Up to 70% HIV-Syphilis Co-Infection in MSM

• First Such Test to be USAID-approved

• Strong Start and Outlook  2014

• Anticipate FDA PMA Submission in 2014

Slide 13

OEM & License Agreements Expanding Relationships and Sales Opportunities

Oswaldo Cruz Foundation

• Five DPP® Products , ~$6MM 2013 revenues

• Brazilian MOH Supplier

Collaboration with LabTest Brazil

• Assembly & Distribution - DPP® Co-branded

• 2014 Plan = Initial Products Registrations

Agreement with RVR Malaysia

• License, Distribution, Tech. Transfer and Contract Manufacturing

 Bio-Rad Laboratories

• Exclusive Licensee for DPP® HIV Confirmatory Application

• CE Marked 2013, FDA Pending

Slide 14

Commercial Strategy: Top Line Growth (Sales)

Build a Sales & Marketing Organization to Increase Our Revenue and Maximize Profits

Tactic #1:   Move up Value Stream in US Diagnostics Market "USA Direct" for Certain Products

Tactic #2:   Future Growth – New Markets and New Applications

Tactic #3:   Maximize Opportunities in Developing World Markets

Slide 15

Additional Priorities & Areas of Focus:  Technology

Technology  Investment

• New Product Launch (DPP® HIV/SYP)

• Develop New Technologies (HIV 4G, HCV) that Address Healthcare Concerns

• Identify Additional Technologies to License/Acquire that will Complement our Commercial Strategy

See graphics

Slide 16

Organization & Facility

• FDA- and USDA-Approved Development & Manufacturing Facility

• All Company Operations in 30,600 Sq. Ft. Leased Facility in Medford, NY

TOTAL EMPLOYMENT: Approximately 200

See graphics

Slide 17

Selected Financial Data FY2009 –2013

2013

Total Revenue $29,550

Product Revenue$ 27,516

Gross Profit $12,300

R&D Expense* $5,834

Pre-Tax Income $530,800

Clinical Trial Expense $1,515

*Non-recurring 2010 $1.5MM R&D Credit from the Affordable Care Act – excluded from 2010 R&D Exp. & 2010 Pre-Tax Income

See graphics

Slide 18

FY2011-2013 - Selected Financial Results

For the Years Ended (in 000's)	Dec 31, 2013				Dec 31, 2012				Dec 31, 2011
Net Product Revenues	$	27,516			$	24,327			$	17,422
Non-Product Revenues		2,034				1,283				1,966
TOTAL REVENUES		29,550				25,610				19,388
GROSS MARGIN		12,300	42	%		10,790	42	%		9,390		48	%
OPERATING COSTS:
Research and Development exp		5,834	20	%		4,486	18	%		4,878		25	%
Selling,General &Administrative exp		5,461	18	%		4,852	19	%		3,424		18	%
		11,295				9,338				8,302
INCOME FROM OPERATIONS		1,005				1,452				1,088
Income tax (benefit) provision		487				509				(5,133	)
NET INCOME	$	531	2	%	$	941	4	%	$	6,209		32	%
Diluted earnings (loss) per share	$	0.06			$	0.11			$	0.73
Weighted avg shs outstanding-diluted		8,994,080				8,614,944				8,556,284

Slide 19

CEMI Selected Share & Balance Sheet Data$6MM Common Stock Public Offering Closed on April 3, 2013 1.2MM Shares @ $5.00 per share, $5.450MM Net Proceeds

in millions except per share and daily volume data
Ticker Symbol (NASDAQ)	CEMI
Price 02/28/14	$	3.80
52-Week High	$	5.70
52-Week Low	$	2.98
Outstanding Shares		9.32
Market Capitalization	$	35.43
Fully Diluted Shares		9.99
Management's Holdings		1.51
Avg. Daily Volume (3 mos. to 02/28/14)		47,000

                                                                                                                                                  ($ in 000s)Dec.'13     Dec.'12

Cash	$	9,650	$	2,952
Total Current Assets		18,531		4,821
Total Assets		24,487		17,335
Total Current Liabilities		4,310		3,378
Total Liabilities		4,310		3,460
Stockholders' Equity		20,177		13,875
Total Liabilities & Stockholders' Equity		24,487		17,335

Options- Mgmt. & BoardTotalAvg. Ex. Price

533K669K    $2.70

Slide 20

2013 - 2014 YTD Milestones Achieved

Product Development/Regulatory

• Received FDA PMA Approval of DPP Oral Fluid HIV Test

• Substantial Progress on CLIA waiver studies

• Received CE Mark for Sure Check HIV 1/2 Assay

• USAID Approval, Initial Sales of HV-Syphilis Test

Corporate/Operations

• Achieved  Fifth Straight Year of Sales Growth and Profitability with Strong Gains in Domestic and International Segments

• Strengthened Balance Sheet with Common Stock Issuance, Establishing Institutional Shareholder Base

• Increased Production Capacity to Meet Sales Growth

Commercialization

• Entered International Assembly & Distribution Agreement w/Labtest of Brazil

• Established Distribution, License , Tech. Transfer, Contract Manufacturer in Asia

• Initial International Registrations for HIV-Syphilis ; Receiving Significant Initial Orders

Slide 21

Anticipated Milestones - 2014

Product Development/Regulatory

• Oral Fluid HIV Test CLIA Waiver & Launch

• CE Marks for HIV 1/2 STAT-PAK®,  DPP® HIV & HIV-Syphilis Products

• International Sales Growth of DPP ® HIV-Syphilis Test

• FDA Submission & Approval of DPP® HIV-Syphilis Test

Corporate/Operations

• Increase Production Capacity

• Pursue Acquisitions or Licenses of Complementary Products/Technologies

• Announcement of New CEO

Commercialization

• Implement US & International Commercial Strategy, Expand Market and Sales Opportunities

• Expand International Revenues for Lateral Flow and DPP® Products

• New Distribution, Contract Development & OEM Deals

Slide 22

Leadership Executive Team

Executive:  Lawrence Siebert, J.D.  Chairman  & CEO

Previous Experience: 1981-1991, Partner, Stanwich Partners, Inc.; 1992-2002 Siebert

 Associates LLC, Manager; Siebert Capital Corp., President

Joined:  2002

Executive:  Richard Larkin, CPA  Chief Financial Officer

Previous Experience: 2000-2003  CFO of Visual Technology Group; 1987-2000 CFO of Protex  International Corp.

Joined:  2003

Executive:  Sharon Klugewicz, M.S.  Chief Operating Officer

Previous Experience: 20+ Years at Pall Corporation, most recently as Sr. VP - Scientific & Laboratory Services

Joined:  2012

Executive:  Javan Esfandiari, M.S.  SVP Research & Development

Previous Experience: 1993-1997, R&D Director On-Site Biotech;

1997-2000, Co-Founder of Sinovus Biotech AB (Sweden), which was acquired by Chembio in 2000

Joined:  2000

Executive:  Thomas Ippolito, VP Regulatory & Clinical Affairs

Previous Experience: 25 years experience in the development of vaccines, therapeutics and IVDs working with several major pharmaceutical, vaccine and diagnostic companies

Joined:  2005

Executive:  Michael Steele, VP Sales Marketing and Business Development

Previous Experience: 20 years of business development and strategy execution at life sciences companies Sera Care Life Sciences, Serologicals, Inc. and Corautus Genetics.

Joined:  2012

Slide 23

Investment Summary

• Develops, Manufactures & Markets Point-of-Care Diagnostic Tests (POCTs)

‐ Global Sales – Direct and Through Partnerships

‐ $8B Global Market with Current Pipeline Addressing $650MM Segment

• Five Consecutive Years of Profitability & Revenue Growth

‐ 2013 Revenues and Product Gross Margin Increased by 15% and 8% respectively vs. 2012

• Patented DPP® - A Platform POCT Technology

‐ Uniquely Enables Multiplexing for Higher Value Tests & Increased Sensitivity

‐ DPP® Oral Fluid HIV Test – FDA-Approved - CLIA waiver pending

‐ DPP® HIV-Syphilis  Test- Strong outlook for international sales in 2014

• Pipeline  of DPP® Products

‐ DPP® HCV Ab & HIV Ag-Ab Test

EX-99.3

PAGE 1

Investor Fact Sheet

Ticker Symbol: NASDAQ: CEMI

www.chembio.com

Business Summary & Investment Highlights

Chembio Diagnostics, Inc., (Chembio),through its wholly-owned subsidiary Chembio Diagnostic Systems, Inc. develops, manufactures, licenses and markets point-of-care testing (POCT) products.  Chembio created and patented a new revolutionary technology called Dual Path Platform (DPP®). The technology is addressing critical market requirements in the infectious diseases testing market and other growing markets. Products under development, both OEM and branded, are anticipated to create significant new revenue streams that will add to Chembio's core business of rapid HIV tests.

· Ten Consecutive Years of Double Digit Revenue Growth and Five Consecutive Years of Profitability.

· Strategy is to create core business of public health products to be complemented by OEM and selected out-licensing opportunities.

· Robust pipeline of POCT products for infectious diseases based on Chembio's patented DPP® technology.

· Products developed on DPP® platform include oral fluid HIV test approved by FDA in December 2012.   Unique multiplex HIV-Syphilis test will be submitted and undergo US FDA regulatory evaluations in 2014.  Several other products and collaborations in pipeline.

· Commercial Activities in North America, South America, Europe, Africa and Asia Ongoing to Address Growing Global Market for POCTs

Selected Financial Information

Stock Information

Ticker Symbol: NASDAQ: CEMI

Price 02/28/2014:   $3.80

52 Week High:   $5.70

52 Week Low: $2.98

Outstanding Shares (MM): 9.32

Market Capitalization (MM): $35.43

Fully Diluted (FD) Shares (MM): 9.99

Management Holding-FD (MM): 1.51

Average Daily Vol. (3 Mos):  47,000

Major Beneficial Holders Beneficial Shares Owned (MM)

Lawrence Siebert: 820

Wellington Management Company, LLP: 671  as of 12/31/12

Norman H. Pessin: 450

Balance Sheet Data ($000s)	Dec'13		Dec.'12
Cash	$	9,650	$	2,952
Accts. Receivable		4,592		4,821
Inventories		3,189		2,488
Other Current Assets		1,100		747
Total Current Assets		18,531		11,008
Net Fixed Assets		1,978		1,428
Other Assets		3,978		4,899
Total Assets		24,487		17,335
Total Current Liab.		4,310		3,378
Total Other Liab.		-		82
Total Liabilities		4,310		3,460
Stockholders' Equity		20,177		13,875
Total Liabilities & Stockholders' Equity	$	24,487	$	17,335

See Graphics

Quarter/Year Ended			For the Years Ended
$	(000s	)		2013			2012			2011			2010			2009
Total Revenues			$	29,550		$	25,611		$	19,388		$	16,705		$	13,834
Cost of sales				17,249			14,821			9,998			8,604			7,974
Gross Profit				12,301			10,790			9,390			8,101			5,860
				41.6	%		42.1	%		48.4	%		48.5	%		42.4	%
R&D Expense				5,834			4,486			4,878			2,586			2,884
SG&A Expense				5,461			4,852			3,424			2,941			2,659
Operating Income (Loss)				1,006			1,452			1,088			2,574			317
Other Inc. (Expense)				13			(1	)		(12	)		(15	)		(8	)
Net Income (Loss)				1,019			1,451			1,076			2,559			309
Inc Tax (Ben.) Prov.				487			509			(5,133	)		-			-
Net Income (Loss)			$	532		$	942		$	6,209		$	2,559		$	309
Net Income (Loss) - per Share			$	0.06		$	0.11		$	0.73		$	0.29		$	0.03
Wt. Avg. No. Shares (Millions)				9.520			8.615			8.556			8.865			9.380
Working capital			$	14,221		$	7,630		$	6,134		$	4,560		$	1,494
Total assets				24,487			17,335			15,486			9,086			6,315
Total liabilities				4,310			3,460			2,991			3,277			3,227
Equity				20,177			13,875			12,495			5,809			3,088

Chembio Diagnostics, Inc.	Investor Relations	Company Contact
3661 Horseblock Road	Vida Strategic Partners	Susan Norcott
Medford, NY 11763	Stephanie C. Diaz	631-924-1135 x125
Ph. 631-924-1135	(415) 675-7401	snorcott@chembio.com
Fax 631-924-2065	sdiaz@vidasp.com
www.chembio.com

PAGE 2 – See Graphics

DPP® Technology

Competitive Advantages For POC Testing

• Improved Sensitivity- enabled by more efficient binding method

• Easier Multiplexing- due to even and direct distribution of sample to multiple test lines

• Enhanced Sample Control- as result of independent sample migration path

• Clearer Results - efficient binding allows for improved functionality of instruments for reading and reporting of qualitative or quantitative results

Chembio's Dual Path Platform (DPP®) Patented in 2007  (see graphic)

Chembio's Lateral Flow Rapid HIV Tests Marketed Exclusively in the USA by Alere North America, Inc.

Senior Management Team

Lawrence A. Siebert, Chairman & CEO, over 25 years of management and financing experience

Richard J. Larkin, CFO, over 25 years of operational and financial experience

Javan Esfandiari, SVP R&D, over 15 years of experience in development of in-vitro point-of- care products

Sharon Klugewicz, COO, over 20 years of experience with Pall Corp.

Independent Members of Board of Directors

Katherine Davis - Former Lieutenant Governor and numerous other leadership positions for the State of Indiana; former senior executive of Cummins, Inc. (NYSE:CMI)

Dr. Gary Meller - Broad experience in medical and information technology and pharmaceutical product development

Dr. Barbara DeBuono – Former New York Commissioner of Health and Rhode Island Director of Health; other positions in domestic and international medical services

Dr. Peter Kissinger – Has founded and/or led 3 biotechnology and/or biomedical technology companies, including a publicly-traded NASDAQ company

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements, the accuracy of which is subject to risks and uncertainties. Please refer to Chembio Diagnostic's Inc. most recent Form 10-K and Forms 10-Q for additional information about the Company and related risks. –March 2014